prasugrel


Also found in: Medical, Wikipedia.
Translations

prasugrel

n prasugrel m
References in periodicals archive ?
Patients in either of these categories metabolize enough clopidogrel into the active form to get full benefit from the drug and derive no additional efficacy benefit from switching to another P2Y12 inhibitor, such as ticagrelor or prasugrel (Effient)--drugs unaffected by metabolizer status.
Contract notice: open house drug discount agreements prasugrel atc b01ac22.
Medications commonly given after placement of a stent include Clopidogrel (Plavix), ticagrelor (Brilinta), prasugrel (Effient), and aspirin.
The comprehensive new version reflects current best practices for using aspirin combined with P2Y12 receptor inhibitors clopidogrel, prasugrel or ticagrelor, and includes a review of 11 studies of patients treated with coronary stent implantation done predominately with drug-eluting stents to assess the risks and benefits of shorter-versus longer-duration dual antiplatelet therapy.
Unfortunately, they are less likely than men to be given a drug to prevent blood clots, such as prasugrel (Effient[R]).
Platelet P2Y12 inhibitors (ticlopidine, clopidogrel, prasugrel, and ticagrelor) are used in the management of patients with coronary artery disease (CAD) who experience acute coronary syndrome (ACS) and/or undergo percutaneous coronary intervention (PCI) and to prevent stroke.
However, prasugrel and ticagrelor should not be used in such patients because the use of these agents has not been studied yet as an adjunctive treatment in fibrinolysis (2, 4).
Either ticagrelor (Brilinta) at 90 mg twice daily or prasugrel (Effient) once daily at 10 mg is recommended over clopidogrel at 75 mg/day in patients who can take those medications safely; this guidance is based on ticagrelor's superior efficacy compared with clopidogrel as shown in TRITON TIMI-38 (N.
This finding of a significant benefit from ticagrelor in post-MI patients with diabetes confirms similar, prior findings with other antiplatelet drugs (including clopidogrel, prasugrel, and vorapaxar) and prior findings with ticagrelor, Dr.
Optimizing P2Y-receptor inhibition in acute coronary syndrome patients based on platelet function testing: impact of prasugrel and high-dose clopidogrel.
Due to financial constraints, ticagrelor or prasugrel could not be prescribed.